# ProtoKinetix, Inc.: financial statements, quarterly

PKTX · OTC · CIK 1128189 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pktx.md) · [Financials](/companies/pktx/financials.md) · [Filings](/companies/pktx/filings.md) · [Insiders](/companies/pktx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pktx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [22.7](/filings/0001079973-24-000714.md) | [32.0](/filings/0001079973-24-001123.md) | [21.3](/filings/0001079973-24-001493.md) | [36.5 d](/filings/0001079973-25-000516.md) | [36.6](/filings/0001079973-25-000816.md) | [21.0](/filings/0001079973-25-001254.md) | [21.0](/filings/0001079973-25-001708.md) | [21.0 d](/filings/0001079973-26-001218.md) | [33.8](/filings/0001079973-25-000816.md) | [24.4](/filings/0001079973-25-001254.md) | [24.2](/filings/0001079973-25-001708.md) | [24.2 d](/filings/0001079973-26-001218.md) |
| Operating income | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(107)](/filings/0001079973-24-000714.md) | [(116)](/filings/0001079973-24-001123.md) | [(80.4)](/filings/0001079973-24-001493.md) | [(112) d](/filings/0001079973-25-000516.md) | [(92.0)](/filings/0001079973-25-000816.md) | [(85.1)](/filings/0001079973-25-001254.md) | [(84.6)](/filings/0001079973-25-001708.md) | [(103) d](/filings/0001079973-26-001218.md) | [(97.7)](/filings/0001079973-25-000816.md) | [(91.1)](/filings/0001079973-25-001254.md) | [(84.9)](/filings/0001079973-25-001708.md) | [(120) d](/filings/0001079973-26-001218.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001079973-24-000714.md) | [(0.01)](/filings/0001079973-24-001123.md) | [(0.01)](/filings/0001079973-24-001493.md) | not reported | [0.00](/filings/0001079973-25-000816.md) | [0.00](/filings/0001079973-25-001254.md) | [0.00](/filings/0001079973-25-001708.md) | not reported | [0.00](/filings/0001079973-25-000816.md) | [0.00](/filings/0001079973-25-001254.md) | [0.00](/filings/0001079973-25-001708.md) | not reported |
| Basic EPS | $ per share | [(0.01)](/filings/0001079973-24-000714.md) | [(0.01)](/filings/0001079973-24-001123.md) | [(0.01)](/filings/0001079973-24-001493.md) | not reported | [0.00](/filings/0001079973-25-000816.md) | [0.00](/filings/0001079973-25-001254.md) | [0.00](/filings/0001079973-25-001708.md) | not reported | [0.00](/filings/0001079973-25-000816.md) | [0.00](/filings/0001079973-25-001254.md) | [0.00](/filings/0001079973-25-001708.md) | not reported |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: not reported
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $k | [8.0](/filings/0001079973-23-000595.md) | [19.7](/filings/0001079973-23-000958.md) | [13.4](/filings/0001079973-23-001455.md) | [21.5](/filings/0001079973-24-001493.md) | [3.9](/filings/0001079973-24-000714.md) | [3.3](/filings/0001079973-24-001123.md) | [6.7](/filings/0001079973-24-001493.md) | not reported | not reported | not reported | not reported | not reported |
| Total assets | $k | [447](/filings/0001079973-23-000595.md) | [467](/filings/0001079973-23-000958.md) | [451](/filings/0001079973-23-001455.md) | [481](/filings/0001079973-25-000516.md) | [461](/filings/0001079973-24-000714.md) | [474](/filings/0001079973-24-001123.md) | [479](/filings/0001079973-24-001493.md) | [466](/filings/0001079973-26-001218.md) | [529](/filings/0001079973-25-000816.md) | [474](/filings/0001079973-25-001254.md) | [478](/filings/0001079973-25-001708.md) | [483](/filings/0001079973-26-001218.md) |
| Current liabilities | $k | [53.0](/filings/0001079973-23-000595.md) | [13.3](/filings/0001079973-23-000958.md) | [12.6](/filings/0001079973-23-001455.md) | [44.7](/filings/0001079973-25-000516.md) | [67.6](/filings/0001079973-24-000714.md) | [58.8](/filings/0001079973-24-001123.md) | [87.7](/filings/0001079973-24-001493.md) | [124](/filings/0001079973-26-001218.md) | [152](/filings/0001079973-25-000816.md) | [149](/filings/0001079973-25-001254.md) | [227](/filings/0001079973-25-001708.md) | [185](/filings/0001079973-26-001218.md) |
| Total liabilities | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $k | [394](/filings/0001079973-24-001123.md) | [454](/filings/0001079973-24-001493.md) | [438](/filings/0001079973-24-001493.md) | [436](/filings/0001079973-26-001218.md) | [394](/filings/0001079973-25-001254.md) | [415](/filings/0001079973-25-001708.md) | [392](/filings/0001079973-25-001708.md) | [342](/filings/0001079973-26-001218.md) | [376](/filings/0001079973-25-001254.md) | [325](/filings/0001079973-25-001708.md) | [250](/filings/0001079973-25-001708.md) | [298](/filings/0001079973-26-001218.md) |

- Cash and equivalents: not reported
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(84.9)](/filings/0001079973-24-000714.md) | [(144) d](/filings/0001079973-24-001123.md) | [(69.9) d](/filings/0001079973-24-001493.md) | [(77.5) d](/filings/0001079973-25-000516.md) | [(57.8)](/filings/0001079973-25-000816.md) | [(80.9) d](/filings/0001079973-25-001254.md) | [(39.1) d](/filings/0001079973-25-001708.md) | [(45.2) d](/filings/0001079973-26-001218.md) | [(52.0)](/filings/0001079973-25-000816.md) | [(80.1) d](/filings/0001079973-25-001254.md) | [(3.9) d](/filings/0001079973-25-001708.md) | [0.6 d](/filings/0001079973-26-001218.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q3 FY2021 (2021-09-30) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [293](/filings/0001079973-21-001122.md) | [291](/filings/0001079973-23-000958.md) | [291](/filings/0001079973-23-001455.md) | [325](/filings/0001079973-24-000714.md) | [336](/filings/0001079973-24-001123.md) | [336](/filings/0001079973-24-001493.md) | [333](/filings/0001079973-25-000816.md) | [354](/filings/0001079973-25-001254.md) | [365](/filings/0001079973-25-001708.md) | [374](/filings/0001079973-25-000816.md) | [354](/filings/0001079973-25-001254.md) | [389](/filings/0001079973-25-001708.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 411,630,152 at 2026-09-02, from the cover of the [10-K filed 2026-09-03](/filings/0001079973-26-001218.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.